Literature DB >> 20811898

Influence of acute and chronic myocardial loading conditions, function, structural changes and extracardiac factors on NT-proBNP in asymptomatic patients with preserved ejection fraction.

Olaf Schulz1, Andre Rudolph, Sarah Scheiner, Helena Mut, Jeanette Schulz-Menger, Gunnar Berghoefer, Ricarda Bensch, Jochen Kraemer, Ingolf Schimke.   

Abstract

BACKGROUND: We compared the effect of different loading conditions, parameters of structural heart disease and extracardiac confounders on NT-proBNP to validate the application of NT-proBNP for a characterisation of loading conditions and clinical course of patients with chronic heart diseases.
METHODS: NT-proBNP was measured in 15 controls and 34 patients with preserved ejection fraction and chronic pressure (by aortic stenosis) or volume overload (by aortic or mitral regurgitation) before and after physical as well as dobutamine stress. Myocardial fibrosis was evaluated by contrast-enhanced cardiovascular magnetic resonance.
RESULTS: In patients with elevated NT-proBNP due to chronic pressure or volume overloaded ventricles, physical and dobutamine stress were associated with only marginal nonsignificant additional NT-proBNP responses. Univariate analyses showed that myocardial fibrosis has the greatest effect on NT-proBNP (P < 0.01). Forward regression analyses revealed left ventricular filling, systolic function, the presence of valvular heart disease, serum creatinine and responses to dobutamine stress as independent determinants of NT-proBNP (P < 0.05 each).
CONCLUSION: NT-proBNP cannot be used simply to characterise intensity of ventricular load. Character and duration of loading conditions, cardiac structure and function, as well as confounders should be considered when NT-proBNP is used for clinical follow-up assessment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20811898     DOI: 10.1007/s00392-010-0210-2

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  34 in total

1.  Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study.

Authors:  S R Ommen; R A Nishimura; C P Appleton; F A Miller; J K Oh; M M Redfield; A J Tajik
Journal:  Circulation       Date:  2000-10-10       Impact factor: 29.690

2.  Responses of atrial natriuretic peptide and brain natriuretic peptide to exercise in patients with chronic heart failure and normal control subjects.

Authors:  I C Steele; G McDowell; A Moore; N P Campbell; C Shaw; K D Buchanan; D P Nicholls
Journal:  Eur J Clin Invest       Date:  1997-04       Impact factor: 4.686

3.  N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study.

Authors:  Rudolf Berger; Deddo Moertl; Sieglinde Peter; Roozbeh Ahmadi; Martin Huelsmann; Susan Yamuti; Brunhilde Wagner; Richard Pacher
Journal:  J Am Coll Cardiol       Date:  2010-02-16       Impact factor: 24.094

4.  Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction.

Authors:  Jens Peter Goetze; Rasmus Mogelvang; Lars Maage; Henrik Scharling; Peter Schnohr; Peter Sogaard; Jens F Rehfeld; Jan Skov Jensen
Journal:  Eur Heart J       Date:  2006-11-21       Impact factor: 29.983

5.  Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology.

Authors:  Alec Vahanian; Helmut Baumgartner; Jeroen Bax; Eric Butchart; Robert Dion; Gerasimos Filippatos; Frank Flachskampf; Roger Hall; Bernard Iung; Jaroslaw Kasprzak; Patrick Nataf; Pilar Tornos; Lucia Torracca; Arnold Wenink
Journal:  Eur Heart J       Date:  2007-01-26       Impact factor: 29.983

Review 6.  Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results.

Authors:  Alan H B Wu
Journal:  Am Heart J       Date:  2006-11       Impact factor: 4.749

Review 7.  B-type natriuretic peptides: a diagnostic breakthrough for clinicians.

Authors:  Peter A McCullough; Torbjørn Omland; Alan S Maisel
Journal:  Rev Cardiovasc Med       Date:  2003       Impact factor: 2.930

8.  Relation of tissue Doppler-derived myocardial velocities to serum levels and myocardial gene expression of tumor necrosis factor-alpha and inducible nitric oxide synthase in patients with ischemic cardiomyopathy having coronary artery bypass grafting.

Authors:  Dinesh K Kalra; Mahesh Ramchandani; Xi Zhu; Gerald Lawrie; Michael J Reardon; Douglas L Mann; William A Zoghbi; Sherif F Nagueh
Journal:  Am J Cardiol       Date:  2002-10-01       Impact factor: 2.778

9.  Basal and exercise-induced neuroendocrine activation in patients with heart failure and in normal subjects.

Authors:  Andreas Kjaer; Jon Appel; Per Hildebrandt; Claus Leth Petersen
Journal:  Eur J Heart Fail       Date:  2004-01       Impact factor: 15.534

10.  Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia.

Authors:  Marc S Sabatine; David A Morrow; James A de Lemos; Torbjorn Omland; Milind Y Desai; Milenko Tanasijevic; Christian Hall; Carolyn H McCabe; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2004-11-16       Impact factor: 24.094

View more
  3 in total

1.  Safety and efficacy of the subclavian access route for TAVI in cases of missing transfemoral access.

Authors:  Andrea Muensterer; Domenico Mazzitelli; Hendrik Ruge; Anke Wagner; Ina Hettich; Nicolo Piazza; Ruediger Lange; Sabine Bleiziffer
Journal:  Clin Res Cardiol       Date:  2013-05-11       Impact factor: 5.460

2.  N-terminal pro-B-type natriuretic peptide in the circulation of fetuses with cardiac malformations.

Authors:  Waltraut M Merz; Kirsten Kübler; Eike Albers; Birgit Stoffel-Wagner; Ulrich Gembruch
Journal:  Clin Res Cardiol       Date:  2011-09-29       Impact factor: 5.460

3.  Exercise tolerance in asymptomatic patients with moderate-severe valvular heart disease and preserved ejection fraction.

Authors:  Schulz Olaf; Brala Debora; Bensch Ricarda; Berghöfer Gunnar; Krämer Jochen; Ingolf Schimke; Martin Halle; Allan Jaffe
Journal:  Arch Med Sci       Date:  2012-12-19       Impact factor: 3.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.